Penn Medicine Provider
Medical Oncology
Ronac Mamtani, MD, MSCE
5.0
(164)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858

About me

  • Section Chief, Genitourinary Cancers, Hematology-Oncology
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: State University of New York at Stony Brook
  • Residency: NewYork-Presbyterian/Weill Cornell Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

164 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

July 2025
5.0
5.0
professional
July 2025
5.0
5.0
Dr Mamtani has a great bedside manner. explains everything fully, answers questions and shows empathy
June 2025
5.0
5.0
very personable
June 2025
5.0
5.0
easy to talk to

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Mamtani is a Penn Medicine physician.

Qualifications and experience

My research

Chow RD, Mamtani R. Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma , Urol Oncol: 2025

Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R. Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies , JAMA Netw Open, 8: 2025,e2520726

Lian Y, Voruganti T, Lu J, Long Q, Mamtani R. Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates , JAMA Netw Open, 8: 2025,e2519524

Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R. Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer , J Natl Cancer Inst, 117: 2025,1276-1278

Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ. Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer , JAMA Netw Open, 8(6): 2025,e2515087

Barsouk AA, Yang A, Sussman JH, Elghawy O, Xu J, Xu J, Meng L, Koga S, Du W, Mamtani R, Mei L. Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis , Clin Genitourin Cancer, 23: 2025,102395

Kurian M, Nimgaonkar V, Elghawy O, Mamtani R. Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC) , American Society of Clinical Oncology Annual Meeting I 2025, Chicago, IL. Poster Presentation., 43(16): 2025

Kurian M, Ferrell WJ, Ulloa Perez E, Hubbard R, Joffe S, Mamtani R*, Parikh RB, Lynch HF. Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis , BMJ Oncol, 4(1): 2025,e000659

Wang X, Long JB, Rothen J, Huang S, Soulos P, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Ma SM, Wang SY, Dinan MA, Gross CP. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. , American Society of Clinical Oncology Annual Meeting I 2025, Chicago IL. Poster Presentation., 43(16): 2025

Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA. Adoption of Broad Genomic Profiling in Patients With Cancer , JAMA Oncol: 2025